1. Home
  2. ITRI vs NAMS Comparison

ITRI vs NAMS Comparison

Compare ITRI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Itron Inc.

ITRI

Itron Inc.

HOLD

Current Price

$97.67

Market Cap

4.4B

Sector

Industrials

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$34.04

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITRI
NAMS
Founded
1977
2019
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
4.0B
IPO Year
1993
N/A

Fundamental Metrics

Financial Performance
Metric
ITRI
NAMS
Price
$97.67
$34.04
Analyst Decision
Buy
Strong Buy
Analyst Count
10
10
Target Price
$135.78
$46.40
AVG Volume (30 Days)
538.1K
907.1K
Earning Date
02-24-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
14.43
N/A
EPS
5.57
N/A
Revenue
$2,408,401,000.00
$35,243,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.62
N/A
P/E Ratio
$17.36
N/A
Revenue Growth
0.14
4.91
52 Week Low
$90.11
$14.06
52 Week High
$142.00
$42.00

Technical Indicators

Market Signals
Indicator
ITRI
NAMS
Relative Strength Index (RSI) 50.72 42.55
Support Level $92.69 $32.67
Resistance Level $97.09 $35.70
Average True Range (ATR) 2.05 1.50
MACD 0.66 -0.10
Stochastic Oscillator 93.96 31.72

Price Performance

Historical Comparison
ITRI
NAMS

About ITRI Itron Inc.

Itron Inc provides solutions that measure, manage, and analyze energy and water use. It operates under the Itron brand and manages and reports under three operating segments: Device Solutions, Networked Solutions, and Outcomes. The Device Solutions segment includes hardware products used for measurement, control, or sense that do not have communications capability embedded for use with broader Itron systems. The Networked Solutions segment includes a combination of communicating devices, network infrastructure, and associated application software designed and sold as a complete solution. The Outcome segment includes their value-added, enhanced software and services which manage, organize, analyze, and interpret data to improve decision-making and maximize operational profitability.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: